On June 12, 2019, 15 members of the U.S. Senate introduced S.1801 (116th Congress), a bill to make medicines more affordable. Among the provisions of the bill, which also include a study of delinkage of R&D financing from pricing, is a Innovation Incentive Fund for New and More Effective Treatments for Bacterial Infections. Section 301 Read more about S.1801 Proposes “Innovation Incentive Fund for New and More Effective Treatments for Bacterial Infections.” Proposal delinks incentives from prices.[…]